li001

Annamycin Combination Therapy Shows Overall Survival Promise in Acute Myeloid Leukemia (AML)Treatment

Treatment /

The AnnAraC combination of annamycin and cytarabine demonstrated encouraging activity in AML patients in the phase 1/2 MB-106 trial, suggesting potential survival benefits. Across first- through seventh-line settings, the median overall survival (OS) was nine months in the 22-patient intention-to-treat population. Patients achieving complete remission (CR, n=8) had a median OS of 15 months, with […]

Annamycin Combination Therapy Shows Overall Survival Promise in Acute Myeloid Leukemia (AML)Treatment Read More »

Adjuvant Abemaciclib Plus Endocrine Therapy Extends Overall Survival in High-Risk HR+/HER2– Breast Cancer

Treatment /

PThe phase 3 monarchE trial demonstrates that adjuvant abemaciclib combined with two years of endocrine therapy significantly improves overall survival in high-risk, node-positive HR+/HER2– early breast cancer patients. The 7-year landmark analysis confirmed sustained benefits in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). monarchE enrolled 5,637 patients across two cohorts. Cohort 1 (n=5,120)

Adjuvant Abemaciclib Plus Endocrine Therapy Extends Overall Survival in High-Risk HR+/HER2– Breast Cancer Read More »

FDA Accepts Gedatolisib NDA for Review in HR+/HER2–, PIK3CA Wild-Type Breast Cancer

Drug Approvals /

The FDA has accepted the NDA for gedatolisib under its Real-Time Oncology Review program for HR+/HER2– advanced breast cancer, based on data from the phase 3 VIKTORIA-1 trial in PIK3CA wild-type patients. In the trial, gedatolisib plus fulvestrant and palbociclib reduced progression risk by 76% compared with fulvestrant alone (HR 0.24; P < .0001), achieving

FDA Accepts Gedatolisib NDA for Review in HR+/HER2–, PIK3CA Wild-Type Breast Cancer Read More »

Darolutamide in Metastatic Castration-Sensitive Prostate Cancer: Clinical Impact and Therapeutic Advances

Treatment /

Darolutamide (Nubeqa) is a novel therapy for metastatic castration-sensitive prostate cancer (mCSPC), a stage where cancer has spread but remains responsive to testosterone-lowering treatments. As a highly selective androgen receptor antagonist, it blocks male hormones that drive tumor growth while minimizing neurological side effects due to its limited penetration of the blood-brain barrier. The drug

Darolutamide in Metastatic Castration-Sensitive Prostate Cancer: Clinical Impact and Therapeutic Advances Read More »

Precision Heat: How Stereotactic Thermal Ablation is Revolutionizing Liver Cancer Treatment

Technology Innovation /

Advanced stereotactic thermal ablation offers a minimally invasive, highly precise treatment for liver tumors. Using heat delivered through needle-like probes—either radiofrequency (RFA) or microwave (MWA)—this approach destroys cancer cells while sparing healthy tissue. Microwave ablation is especially effective for larger tumors due to faster, uniform heating unaffected by blood flow. Stereotactic systems enhance traditional ablation

Precision Heat: How Stereotactic Thermal Ablation is Revolutionizing Liver Cancer Treatment Read More »

Antibody-Drug Conjugates: Targeted Cancer Therapy in Clinical Practice

Targeted Therapy /

Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a potent chemotherapy drug, delivering treatment directly to cancer cells while sparing healthy tissue. Often called “smart bombs,” ADCs improve outcomes across several cancers. An ADC works in four steps: the antibody binds specifically to cancer cell proteins, the complex is internalized,

Antibody-Drug Conjugates: Targeted Cancer Therapy in Clinical Practice Read More »

Artificial Intelligence in Complex Liver Cancer Surgery: Precision Oncological Resection

Technology Innovation /

Artificial intelligence (AI) is transforming complex liver cancer surgery by improving precision and patient outcomes. In preoperative planning, AI creates detailed 3D liver models from CT or MRI scans, accurately mapping tumors, blood vessels, and bile ducts. Surgeons can perform “virtual hepatectomies” to simulate resections, calculate remaining healthy liver tissue, and reduce postoperative liver failure

Artificial Intelligence in Complex Liver Cancer Surgery: Precision Oncological Resection Read More »

Artificial Intelligence in Precision Oncology: Clinical Applications and Patient Outcomes

Precision Medicine /

Artificial intelligence (AI) is revolutionizing precision oncology by analyzing large datasets to guide personalized cancer care. It improves diagnosis, treatment selection, drug development, and risk assessment, leading to better patient outcomes. In diagnostics, AI rapidly interprets medical images and digital pathology slides, detecting subtle patterns and classifying cancer subtypes with high accuracy. It also predicts

Artificial Intelligence in Precision Oncology: Clinical Applications and Patient Outcomes Read More »

CAR-T Cell Therapy: Reprogramming the Immune System to Fight Cancer

Immunotherapy /

CAR-T cell therapy is a personalized immunotherapy that reprograms a patient’s T-cells to recognize and attack cancer. It has transformed treatment for certain blood cancers, providing hope for long-term remission in patients who have not responded to other therapies. The process begins with T-cell collection from the patient’s blood, followed by genetic modification in the

CAR-T Cell Therapy: Reprogramming the Immune System to Fight Cancer Read More »

Clinical trials for bladder cancer

Clinical Trails /

Clinical trials are exploring a range of innovative therapies for bladder cancer, aiming to improve outcomes while preserving the bladder. Intravesical and Targeted Therapies: Oncolytic viruses like cretostimogene grenadenorepvec and EG-70 are designed to selectively kill cancer cells and activate the immune system. Novel drug delivery systems, such as TAR-210, release chemotherapy (e.g., erdafitinib) over time

Clinical trials for bladder cancer Read More »